



MEMO

Date: August 30, 2022
To: External
From: Sick Cells

RE: August 2022 Policy Memo

With most of the Hill being on vacation or recess, August was a quiet policy month for Sick Cells. Nevertheless, we have a few important updates to share about our work.

1. Sick Cells **prepared advocates** for a [Tennessee Pharmacy Advisory Committee Meeting](#) on August 11th.

- a. One advocate, a SCD expert clinician in Tennessee, provided oral testimony.
- b. Sick Cells submitted written testimony.
- c. Current formulary placements for SCD therapies are as follows:

Droxia	Preferred, Open Access
Hydroxyurea	Preferred, Open Access
Endari	Non-preferred, Prior Authorization, Step Therapy & Quantity Limits
Oxbryta	Non-preferred, Prior Authorization, Step Therapy & Quantity Limits
Siklos	Non-preferred, Prior Authorization
Adakveo	Not Listed

- d. **The board did not recommend any changes to the formulary.**

2. The August Ambassador Priority Topic Meeting (PTM) focused on the topic of **Access & Coverage**.

- a. Ambassadors reviewed the basics of insurance coverage & common pain points, and how to make an appeal.

3. Sick Cells **released the final report for our Medicaid research** project

- a. [Medicaid Access & Landscape Review for Prescription Drugs Treating Sickle Cell Disease](#)
- b. Results will be premiered at the [2022 Coverage for SCD Summit](#) on August 31.

See you in September!